Promosyon programı Bachem Holding AG
Genişletilmiş Program
Basit Program
Seviye
Hafife alma
İsim |
Anlam |
Seviye |
P/S |
0.7248 |
10 |
P/BV |
0.3154 |
10 |
P/E |
3.65 |
10 |
Yeterlik
İsim |
Anlam |
Seviye |
ROA |
6.67 |
2 |
ROE |
8.87 |
3 |
ROIC |
0 |
0 |
Temettü
İsim |
Anlam |
Seviye |
Temettü getirisi |
1.86 |
4.65 |
DSI |
0.8333 |
8.33 |
Temettülerin ortalama büyümesi |
-26.41 |
0 |
Görev
İsim |
Anlam |
Seviye |
Debt/EBITDA |
0 |
10 |
Debt/Ratio |
0 |
10 |
Debt/Equity |
0.3822 |
10 |
Büyüme darbesi
İsim |
Anlam |
Seviye |
Gelir, milyar, % |
83.16 |
9 |
Ebitda, % |
69.8 |
8 |
EPS, % |
77.27 |
8 |
Fiyat
|
Fiyat |
Min. |
Maksimum. |
Değiştirmek |
Sektördeki değişiklikler |
Dizindeki değişiklikler |
Dün |
6.1 $ |
0 $ |
0 $ |
+3.44 % |
0 % |
0 % |
Hafta |
6.1 $ |
0 $ |
0 $ |
+3.44 % |
0 % |
0 % |
Ay |
6.29 $ |
0 $ |
0 $ |
+0.3339 % |
0 % |
0 % |
3 ay |
5.5 $ |
6.1 $ |
6.4 $ |
+14.73 % |
0 % |
0 % |
Altı ay |
6.26 $ |
5.18 $ |
6.67 $ |
+0.7987 % |
0 % |
0 % |
Yıl |
9.52 $ |
5.18 $ |
10.18 $ |
-33.73 % |
0 % |
0 % |
3 yıl |
5.18 $ |
5.18 $ |
10.58 $ |
+117.72 % |
0 % |
0 % |
5 yıl |
5.18 $ |
5.18 $ |
10.58 $ |
+117.72 % |
0 % |
0 % |
10 yıl |
5.18 $ |
5.18 $ |
10.58 $ |
+117.72 % |
0 % |
0 % |
Sene başından beri |
6.27 $ |
5.18 $ |
6.71 $ |
+0.638 % |
0 % |
0 % |
Şirketin yönetimi
Amir |
İş unvanı |
Ödeme |
Doğum yılı |
Mr. Thomas Meier |
CEO, COO & Chairman of Group Executive Board |
|
1968 (57 yıl) |
Mr. Alain Schaffter |
Chief Financial Officer |
|
1977 (48 yıl) |
Mr. Michael Suter |
Vice President of Global Accounting |
|
|
Dr. Gunther Loidl |
Chief Technology Officer |
|
1970 (55 yıl) |
Mr. Achim Pluckebaum |
Chief Information Officer |
|
|
Dr. Daniel Grotzky |
Head of Group Communications |
|
|
Viviane Minden |
Chief Human Resources Officer |
|
|
Dr. Anne-Kathrin Stoller Ph.D. |
Chief Operating Officer of Bachem Americas, Inc. |
|
1974 (51 yıl) |
Dr. Torsten Wohr |
Chief Commercial Officer |
|
1968 (57 yıl) |
Mr. Boris Corpataux |
VP & Head Global Strategic Alliances |
|
|
Şirket hakkında Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.